Physician profile
Daniel A Feldman
NPI 1649562307
$1,627.56
in general payments reported to CMS, 2019-2025
19 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $171 · 2021: $62.83 · 2022: $315 · 2023: $141 · 2024: $259 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.02 | 2021-2024 | |
| Allergan, INC. | $221.28 | 2019-2022 | |
| Edwards Lifesciences Corporation | $205.30 | 2019 | |
| Axsome Therapeutics, INC. | $122.03 | 2025 | Symbravo |
| Assertio Therapeutics, INC. | $120.77 | 2020 | |
| Lilly USA, LLC | $102.72 | 2019 | |
| Boston Scientific Corporation | $81.96 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $51.44 | 2022-2023 | Vyepti |
| Siemens Medical Solutions USA, INC. | $50.39 | 2024 | Cios Flow |
| Teva Pharmaceuticals USA, INC. | $46.59 | 2019-2020 | |
| Genentech USA, INC. | $42.20 | 2024 | Ocrevus, Enspryng |
| Ucb, INC. | $37.42 | 2019-2024 | Briviact |
| Amgen INC. | $35.61 | 2019-2022 | |
| Medtronic, INC. | $30.75 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $27.07 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $20.08 | 2022 | |
| Nalu Medical, INC. | $19.84 | 2022 | |
| Janssen Biotech, INC. | $19.07 | 2023 | Tremfya |
| Sk Life Science, INC. | $17.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.